Company intelligence / Profile preview

GAMBIT

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Gambit Bio is a London-based biotechnology company developing a rapid, low-cost diagnostic platform for early cancer detection. The company's technology utilizes lateral flow assays to detect cancer-specific biomarkers in blood or saliva, aiming to make screening as simple and accessible as a pregnancy test. By enabling frequent and affordable testing, Gambit Bio seeks to identify cancers at earlier, more treatable stages, potentially improving patient outcomes and reducing healthcare costs. Their approach focuses on democratizing access to early-stage screening through a scalable and user-friendly diagnostic format.

Therapeutic areas: Oncology
Modalities: Diagnostic testLateral flow assayBiomarker detection
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on GAMBIT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GAMBIT.

Explore the full profile